Cilostazol

Generic Name: Cilostazol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₇N_₅O_₂

CAS Number: 73963-72-1

Unique Ingredient Identifier: N7Z035406B

Background: Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

Indication: Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions: Intermittent Claudication

Associated Therapies: -

Clinical Trials

Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease

Phase 4

Completed

Conditions: Peripheral Vascular Disease
Hemodialysis Patients

Interventions: Drug: Cilostazol

First Posted Date: 2007-02-05

Last Posted Date: 2015-05-12

Lead Sponsor: Tungs' Taichung Metroharbour Hospital

Target Recruit Count: 40

Registration Number: NCT00431249

Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation

Phase 4

Completed

Conditions: Acute Coronary Syndrome

First Posted Date: 2006-11-29

Last Posted Date: 2006-11-29

Lead Sponsor: Shenyang Northern Hospital

Registration Number: NCT00404716

The Use of Cilostazol in Patients With Diabetic Nephropathy

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes Complications

Interventions: Drug: Placebo
Drug: Cilostazol

First Posted Date: 2006-01-09

Last Posted Date: 2009-05-22

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 62

Registration Number: NCT00272831

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

Phase 4

Completed

Conditions: Cerebral Infarction

First Posted Date: 2006-01-06

Last Posted Date: 2009-12-16

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 468

Registration Number: NCT00272454

Locations: 🇰🇷
Hallym University Sacred Heart Hospital, Ahnyang, Kyunggi Province, Korea, Republic of
🇰🇷
Inje University Ilsan Paik Hospital, Koyang, Kyunggi Province, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Sungnam, Kyunggi Province, Korea, Republic of

and more 8 locations

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Phase 4

Completed

Conditions: Cerebral Infarction

Interventions: Drug: Cilostazol
Drug: Aspirin

First Posted Date: 2005-10-06

Last Posted Date: 2011-06-10

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 2800

Registration Number: NCT00234065

Locations: 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)

Phase 3

Conditions: Cardiovascular Diseases
Peripheral Vascular Diseases
Atherosclerosis

Interventions: Device: Stent
Behavioral: Supervised Exercise Therapy
Drug: Cilostazol

First Posted Date: 2005-08-22

Last Posted Date: 2013-04-25

Lead Sponsor: Joselyn Cerezo, MD

Target Recruit Count: 119

Registration Number: NCT00132743

Locations: 🇺🇸
Rapides Regional Medical Center, Alexandria, Louisiana, United States
🇺🇸
VA Palo Alto Health Care Systems, Palo Alto, California, United States
🇺🇸
The Iowa Clinic, Des Moines, Iowa, United States

and more 24 locations

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II

Phase 4

Completed

Conditions: Cerebral Infarction
Atherosclerosis

Interventions: Drug: Cilostazol
Drug: clopidogrel

First Posted Date: 2005-08-15

Last Posted Date: 2010-01-12

Lead Sponsor: Asan Medical Center

Target Recruit Count: 457

Registration Number: NCT00130039

Locations: 🇰🇷
Inje University Ilsan Paik Hospital, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷
Dongguk University International Hospital, Goyang, Kyoungki-do, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Kyunggi, Korea, Republic of

and more 16 locations

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Phase 4

Completed

Conditions: Raynaud's Disease

First Posted Date: 2002-11-11

Last Posted Date: 2005-07-19

Lead Sponsor: Otsuka America Pharmaceutical

Target Recruit Count: 75

Registration Number: NCT00048763

Locations: 🇺🇸
The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
LaRabida Children's Hospital, Chicago, Illinois, United States
🇺🇸
Advanced Medical Clinical Therapeutics, Anchorage, Alaska, United States

and more 15 locations

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Phase 4

Completed

Conditions: Raynaud's Disease

First Posted Date: 2002-11-11

Last Posted Date: 2005-07-19

Lead Sponsor: Otsuka America Pharmaceutical

Target Recruit Count: 75

Registration Number: NCT00048776

Locations: 🇺🇸
Madera Family Medical Group, Madera, California, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸
St. Louis University Health Sciences Center, St. Louis, Missouri, United States

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy